Reference number : GC-2017-Q2-00045, amendment number : , agreement type : G, recipient legal name : Dory, Yves (Université de Sherbrooke), recipient country : CA, recipient province : nan, recipient city : Quebec|Québec, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : In spite of considerable advancement in cancer chemotherapy, the survival rate in brain cancer patients is_x000D_
extremely limited mainly due to the blood-brain barrier (BBB) which prevents the transmission of drug from_x000D_
blood circulation into the brain parenchyma. The present research proposal is based on the conjugation of_x000D_
TRIOZANTM, as a nanomedicine delivery platform under proprietary of Ovensa Inc., with B1R agonist ligand._x000D_
The permeability of B1R-functionalized TRIOZANTM will be evaluated via the measurement of its binding_x000D_
affinity to the endothelial cell receptors. Developed technology will be transferred to Ovensa Inc. as a key step_x000D_
in developing of blood-brain-transient drug delivery platform., program purpose french : In spite of considerable advancement in cancer chemotherapy, the survival rate in brain cancer patients is_x000D_
extremely limited mainly due to the blood-brain barrier (BBB) which prevents the transmission of drug from_x000D_
blood circulation into the brain parenchyma. The present research proposal is based on the conjugation of_x000D_
TRIOZANTM, as a nanomedicine delivery platform under proprietary of Ovensa Inc., with B1R agonist ligand._x000D_
The permeability of B1R-functionalized TRIOZANTM will be evaluated via the measurement of its binding_x000D_
affinity to the endothelial cell receptors. Developed technology will be transferred to Ovensa Inc. as a key step_x000D_
in developing of blood-brain-transient drug delivery platform., agreement title english : Synthesis of TRIOZAN-Peptide Conjugates as Blood-Brain Transient Drug Nanovector, agreement title french : Synthesis of TRIOZAN-Peptide Conjugates as Blood-Brain Transient Drug Nanovector, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-07-12, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada